UniProt P06239 · PDB · AlphaFold · Substrate: pEY + Mn · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Nintedanib | 100.0% | 0.0% | 90.23 | 0.608 |
| 2 | Dasatinib | 100.0% | 0.0% | 87.97 | 0.699 |
| 3 | Ponatinib | 99.7% | 0.3% | 78.23 | 0.534 |
| 4 | Bosutinib | 99.7% | 0.3% | 87.22 | 0.555 |
| 5 | Neratinib | 99.3% | 0.7% | 93.18 | 0.597 |
| 6 | Vandetanib | 98.9% | 1.1% | 95.74 | 0.723 |
| 7 | Repotrectinib | 98.6% | 1.4% | 84.21 | 0.608 |
| 8 | Pacritinib | 98.4% | 1.6% | 88.64 | 0.452 |
| 9 | Vemurafenib | 98.4% | 1.6% | 96.49 | 0.598 |
| 10 | Ibrutinib | 98.0% | 2.0% | 94.74 | 0.723 |
| 11 | Canertinib | 97.7% | 2.3% | 96.49 | 0.671 |
| 12 | Tivozanib | 97.5% | 2.5% | 92.42 | 0.673 |
| 13 | Cabozantinib | 97.5% | 2.5% | 92.73 | 0.751 |
| 14 | Ripretinib | 97.2% | 2.8% | 92.95 | 0.674 |
| 15 | Crizotinib | 96.8% | 3.2% | 91.39 | 0.581 |
| 16 | Nilotinib | 95.1% | 4.9% | 96.49 | 0.765 |
| 17 | Gilteritinib | 94.6% | 5.4% | 88.97 | 0.506 |
| 18 | Dabrafenib | 93.7% | 6.3% | 94.74 | 0.633 |
| 19 | Lenvatinib | 93.4% | 6.6% | 97.74 | 0.726 |
| 20 | Sunitinib | 93.4% | 6.6% | 91.73 | 0.524 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.14
- Epithelial log2(TPM+1): 0.81
- Fold change: -0.68
- Status: No significant change
Selectivity landscape vs inhibition on LCK
Each point is one of the 92 approved drugs; color = inhibition % on LCK.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…